

Alpha Glucosidase Inhibitors Market Size, Share And Growth Analysis For 2024-2033

The Business Research Company's Alpha Glucosidase Inhibitors Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, August 6, 2024 /EINPresswire.com/ --The alpha glucosidase inhibitors market has experienced significant growth in recent years, expanding from \$4.22 billion in 2023 to an expected



\$4.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. This growth has been driven by increased diabetes incidence, heightened awareness of diabetes management, advancements in treatment strategies, and a preference for oral antidiabetic medications. As the market continues to grow, it is forecasted to reach \$6.11 billion by 2028, with a CAGR of 7.5%,



You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs" The Business Research Company due to the emphasis on early intervention, a rising geriatric population, global healthcare initiatives for diabetes control, and integration into combination therapies.

Aging Population Driving Market Growth
The growing aging population is a key driver for the alpha
glucosidase inhibitors market. As this demographic trend
continues, the need for effective diabetes management

becomes more critical. Alpha glucosidase inhibitors help manage blood glucose levels by delaying carbohydrate absorption, a crucial function for older individuals. According to the World Health Organization (WHO), the global population of people aged 60 and older is expected to double by 2050, reaching 2.1 billion, further driving market growth.

Explore comprehensive insights into the alpha glucosidase inhibitors market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=11880&type=smp

Major Players and Market Trends

Major companies in the alpha glucosidase inhibitors market include Pfizer Inc., Roche, Bayer AG,

Novartis AG, Sanofi AS, Bristol Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd., and Eli Lilly and Company, among others. Product innovation is a key trend, with companies developing new products to maintain market positions. For instance, TheracosBio received FDA approval for Brenzavvy (bexagliflozin) in January 2023, a unique oral inhibitor of sodium-glucose cotransporter 2 (SGLT2) for type 2 diabetes management.

Market Segments

- Type: Dumping Syndrome, Type 2 Diabetes
- Drug Class: Acarbose, Miglitol, Voglibose
- Constituent: Glucoamylase, Isomaltase, Maltase, Sucrase
- Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies

Geographical Insights: North America Leads the Market

North America dominated the alpha glucosidase inhibitors market in 2023. The Middle-East is expected to be the fastest-growing region during the forecast period. The detailed report provides insights into regional dynamics, market trends, and growth opportunities.

Explore the report store to make a direct purchase of the report https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

<u>Alpha Glucosidase Inhibitors Global Market Report 2024</u> from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Alpha Glucosidase Inhibitors Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on alpha glucosidase inhibitors market size, alpha glucosidase inhibitors market drivers and trends, alpha glucosidase inhibitors market major players, competitors' revenues, market positioning, and market growth across geographies. The alpha glucosidase inhibitors market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Medical Equipment Maintenance Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/medical-equipment-maintenance-global-market-report

Medication Adherence Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medication-adherence-global-market-report

Biosimilar Therapeutic Peptides Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/733315158

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.